EQUITABLE IMPROVEMENT FOR WOMEN AND MEN IN THE USE OF GUIDELINE-RECOMMENDED THERAPIES FOR HEART FAILURE: FINDINGS FROM IMPROVE HF  by Walsh, Mary Norine et al.
A142.E1330
JACC March 9, 2010
Volume 55, issue 10A
 QUALITY OF CARE AND OUTCOMES ASSESSMENT 
EQUITABLE IMPROVEMENT FOR WOMEN AND MEN IN THE USE OF GUIDELINE-RECOMMENDED 
THERAPIES FOR HEART FAILURE: FINDINGS FROM IMPROVE HF
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Quality of Care - Disparities
Abstract Category: Quality of Care
Presentation Number: 1247-156
Authors: Mary Norine Walsh, Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J Thomas Heywood, Mark 
L. McBride, Christopher M. O’Connor, Patches Johnson Inge, Mandeep R. Mehra, Dwight Reynolds, Clyde W. Yancy, Medtronic, Inc., Minneapolis, MN
Background: While sex-based disparities in use of guideline-recommended heart failure (HF) therapies have been previously described, little is 
known regarding whether performance improvement initiatives produce similar improvements in care for women and men with HF.
Methods: IMPROVE HF is a prospective study of a practice-based performance improvement intervention to enhance use of guideline-
recommended therapies for eligible patients with systolic HF or post-MI LVSD. Mean changes from baseline to 24 months post-intervention were 
analyzed in women and men for ACEI/ARB, -blocker, aldosterone antagonist, anticoagulation for atrial fibrillation, CRT, ICD, and HF education 
quality measures.
Results: The analysis included 15,177 patients at 155 cardiology practices, of which 4383 (28.9%) were women and 10,787 (71.1%) were men. 
At baseline, women were treated less than men for 4 of 7 quality measures. Post-intervention, significant improvements in 6 of 7 quality measures 
were evident at 24 months for both sexes. The absolute magnitude of improvement was similar for 4 measures and significantly better for women in 
2 measures and composite care.
Conclusion: This performance improvement intervention was associated with similar or greater increases in use guideline-recommended therapies 
for eligible women compared with men with HF. Application of clinical decision support and performance feedback may be helpful to ensure 
improved and equitable care for men and women with HF.
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P value
ACEI/ARB 80.0% 86.1% +6.1% 79.3% 87.4% +8.1% 0.107
Beta-Blocker 86.1% 93.6% +7.5% 86.4% 93.5% +7.1% 0.649
Aldosterone Antagonist 33.4% 59.8% +26.4% 36.6% 66.3% +29.8% 0.329
Anticoagulation for Atrial 
Fibrillation
70.1% 70.7% +0.6% 63.9% 64.4% +0.5% 0.986
CRT-P/CRT-D 38.3% 65.8% +27.5% 36.1% 75.2% +39.1% 0.003
ICD/CRT-D 52.2% 80.4% +28.2% 40.7% 75.6% +34.9% <0.001
HF Education 62.6% 71.6% +8.9% 59.7% 69.1% +9.4% 0.734
Composite Score* 69.4% 80.5% +11.1% 66.2% 79.1% +12.9% 0.016
All-or-none care** 25.0% 43.8% +18.8% 22.5% 44.1% +21.6% 0.053
*Composite score was calculated by dividing the sum of the numerator for each care measure by the sum of the denominators for each care 
measure at each practice. **All-or-none care was defined as the percentage of patients at each practice who received all HF care measures for 
which they were eligible.
